Table 1.
Patient Characteristics
| Characteristics (n=105) | |
| Age (years), median (IQR) | 72 (67–77) |
| Male sex, n (%) | 75 (71.4) |
| ECOG PS score, n (%) | |
| 0 | 64 (61.0) |
| 1 | 31 (29.5) |
| ≥2 | 10 (9.5) |
| Primary tumor site, n (%) | |
| Bladder | 42 (40.0) |
| Upper urinary tract | 41 (39.0) |
| Upper urinary tract + bladder | 22 (21.0) |
| Pure UC in histological analysis, n (%) | 85 (81.0) |
| Albumin (g/dl), median (IQR) | 3.8 (3.5–4.2) |
| Visceral metastasis | 61 (58.1) |
| Liver metastasis | 19 (18.1) |
| Treatment line of pembrolizumab | |
| 2nd | 84 (80.0) |
| ≥3rd | 21 (20.0) |
| Increased posttreatment REC (3 weeks later) | 65 (61.9) |
| irAEs | |
| Any grade | 34 (32.4) |
| Grade ≥3 | 11 (10.5) |
| ORR(CR+PR) | 38 (36.2) |
Abbreviations: IQR, interquartile range; ECOG PS, Eastern Cooperative Oncology Group Performance Status; UC, urothelial carcinoma; REC, relative eosinophil count; irAEs, immune-related adverse events; ORR, objective response rate; CR, complete response; PR, partial response.